Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Algorithm of Biological Treatment for Depression in Schizophrenia

Maslenikov Nikita, Tsukarzi Eduard, Mosolov Sergey

Moscow Research Institute of Psychiatry – V. Serbsky NMRCPN, Moscow, Russia

Depression is the most common co-occurring syndrome in schizophrenia associated with worsening of quality of life and course of illness, also with high morbidity and mortality rates. There are number of issues in differential diagnosis of this condition and treatment approaches including both pharmacotherapy and brain stimulation techniques. Brief review of present evidence-based data, including systematic reviews and meta-analyses, as well as recommendations of international expert groups (particularly of World Federation of Societies of Biological Psychiatry – WFSBP) is given in this article. Schematic algorithm of diagnostic and therapeutic options with indication of level of evidence and descriptions is provided in this publication.

Contact: maniki1980@rambler.ru

References: 

1. van Rooijen G., Vermeulen J.M., Ruhé H.G., de Haan L. Treating depressive episodes or symptoms in patients with schizophrenia // CNS Spectrums. – 2018. – P. 1–10. – DOI: 10.1017/S1092852917000554

2. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia // Schizophr Bull. − 2009. − Vol. 35 (2). − P. 383–402.

3. Whitehead C., Moss S., Cardno A., Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review // Psychol Med. − 2003. − Vol. 33 (4). − P. 589–599.

4. Addington J., el-Guebaly N. Group treatment for substance abuse in schizophrenia // Can J Psychiatry. − 1998. − Vol. 43 (8). − P. 843–845.

5. Reine G., Lançon C., Di Tucci S. et al. Depression and subjective quality of life in chronic phase schizophrenic patients // Acta Psychiatr Scand. − 2003, Oct. − Vol. 108 (4). − P. 297−303.

6. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? // Arch Gen Psychiatry. − 2007, Oct. − Vol. 64 (10). − P. 1123−1131.

7. Dzhons P.B., Bakli P.F. Shizofreniya: klinicheskoe rukovodstvo / per. s angl.; pod obshh. red. S.N. Mosolova. − M.: MEDpress-inform, 2009. − 192 s.

8. Mazo G.E`. Vliyanie depressii na techenie shizofrenii // Psixiatriya i psixofarmakoterapiya. − 2006. − T. 8, № 3. − S. 22−24.

9. Mazo G.E`., Gorbachev S.E. Depressiya pri shizofrenii: opy`t i podxody` prakticheskix vrachej k diagnostike i terapii // Social`naya i klinicheskaya psixiatriya. − 2009. − № 4. − S. 5−14.

10. Mazo G.E`., Neznanov N.G. Terapevticheski rezistentny`e depressii. Izd. 2-e, dop. − SPb.: Ladoga, 2013. − 372 s.

11. Mazo G.E`. Depressiya pri shizofrenii: mexanizmy` formirovaniya // Nauch.-prakt. konf. «Psixicheskoe zdorov`e: social`ny`e, kliniko-organizacionny`e i nauchny`e aspekty`»: sb. mater. / pod red. G.P. Kostyuka. − M., 2017. − S. 327−334.

12. Lambert M., Karow A., Leucht S. et al. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later // Dialogues Clin Neurosci. −2010. − Vol. 12 (3). − P. 393–407.

13. Mosolov S.N., Potapov A.V., Ushakov U.V. et al. Design and validation of standardized clinical and functional remission criteria in schizophrenia // Neuropsychiatr Dis Treat. −2014. − Vol. 10. − P. 167–181.

14. Juckel G., de Bartolomeis A., Gorwood Ph. et al. Towards a framework for treatment effectiveness in schizophrenia // Neuropsychiatric Disease and Treatment. − 2014. − No. 10. − P. 1867−1878.

15. Carpenter W.T. jr., Heinrichs D.W., Alphs L.D. Treatment of negative symptoms // Schizophr Bull. − 1985. − Vol. 11. − P. 440–452.

16. Mosolov S.N. Shkaly` psixometricheskoj ocenki simptomatiki shizofrenii i koncepciya pozitivny`x i negativny`x rasstrojstv. − M.: Novy`j czvet, 2001. − 238 s.

17. Mosolov S.N., Czukarzi E`.E`., Alfimov P.V. Algoritmy` biologicheskoj terapii shizofrenii // Sovremennaya terapiya psixicheskix rasstrojstv. − 2014. − № 1. − S. 27−36.

18. Mosolov S.N., Czukarzi E`.E`. Psixofarmakoterapiya shizofrenii // Psixiatriya: nacional`noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. − M.: GE`OTAR-media, 2018. – S. 299−328.

19. Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance // World J Biol Psychiatry. − 2012. − Vol. 13 (5). − P. 318–378.

20. Hausmann A., Fleischhacker W.W. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review // Acta Psychiatr Scand. – 2002. – Vol. 106 (2). –P. 83–96.

21. Lako I.M., Bruggeman R., Knegtering H. et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia // J Affect Disord. − 2012. − Vol. 140 (1). − P. 38−47.

22. Leucht S., Heres S., Kissling W., Davis J.M. Pharmacological treatment of schizophrenia // Fortschr Neurol Psychiatr. − 2013. − Vol. 81 (5). P. e1–13.

23. Abuzzahab F.S. sr., Zimmerman R.L. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia // J Clin Psychiatry. − 1982. − Vol. 43 (3). − P. 105–110.

24. Alfredsson G., Harnryd C., Wiesel F.A. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients – relationship to drug concentrations // Psychopharmacology (Berlin). − 1984. – Vol. 84 (2). − P. 237–241.

25. Dufresne R.L., Valentino D., Kass D.J. Thioridazine improves affective symptoms in schizophrenic patients // Psychopharmacol Bull. − 1993. − Vol. 29 (2). − P. 249–255.

26. Krakowski M., Czobor P., Volavka J. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes // Psychiatry Res. − 1997. − Vol. 71 (1). − P. 19–26.

27. Mauri M.C., Bitetto A., Fabiano L. et al. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs // Prog Neuropsychopharmacol Biol Psychiatry. − 1999. − Vol. 23 (1). − P. 43–54.

28. van Putten T., May R.P. “Akinetic depression” in schizophrenia // Arch Gen Psychiatry. − 1978. − Vol. 35 (9). − P. 1101–1107.

29. Pani L., Gessa G.L. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia // Mol Psychiatry. − 2002. − Vol. 7 (3). − P. 247–253.

30. Altamura A.C., Bassetti R., Bignotti S. et al. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study // Schizophr Res. − 2003. − Vol. 60 (1). − P. 47–55.

31. Falkai P., Wobrock T., Lieberman J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: acute treatment of schizophrenia // World J Biol Psychiatry. −2005. − Vol. 6 (3). − P. 132−191.

32. Mosolov S.N. Osnovy` psixofarmakoterapii. – M.: Vostok, 1996. – 242 s.

33. Mosolov S.N. Klinicheskoe primenenie sovremenny`x antidepressantov. SP,.: Medicinskoe informacionnoe agentstvo, 1995. – 568 s.

34. Dilsaver S.C., Coffman J.A. Cholinergic hypothesis of depression: a reappraisal // J Clin Psychopharmacol. – 1989. – Vol. 9. – P. 173–179.

35. Bermanzohn P.C., Siris S.G. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia // Compr Psychiatry. − 1992, Jul−Aug. − Vol. 33 (4). − P. 221−232.

36. Alfredsson G., Harnryd C., Wiesel F.A. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients – relationship to drug concentrations // Psychopharmacology. – 1984. – Vol. 84. – P. 237–41.

37. Möller H.J. Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues // World J Biol Psychiatry. − 2005. − Vol. 6 (4). − P. 247–263.

38. Furtado V.A., Srihari V. Atypical antipsychotics for people with both schizophrenia and depression // Cochrane Database Syst Rev. – 2008. – Vol. 1. – CD005377.

39. Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol. // European Neuropsychopharmacology. – 2001. – Vol. 11 (3). – P. 264.

40. Riedel M., Mayr A., Seemuller F. et al. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol // World J Biol Psychiatry. − 2012. − Vol. 13 (1). − P. 30–38.

41. Rybakowski J.K., Vansteelandt K., Szafranski T. et al. Treatment of depression in first episode of schizophrenia: results from EUFEST // Eur Neuropsychopharmacol. − 2012. − Vol. 22 (12). − P. 875–882.

42. Leucht S., Arbter D., Engel R.R. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials // Mol Psychiatry. − 2009. − Vol. 14 (4). − P. 429–447.

43. Leucht S., Corves C., Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis // Lancet. − 2009. − Vol. 373 (9657). − P. 31–41.

44. Nasrallah H.A., Cucchiaro J.B., Mao Y. et al. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies // CNS Spectr. − 2015, Apr. − Vol. 20 (2). − P. 140−147.

45. Addington D.E., Mohamed S., Rosenheck R.A. et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia // J Clin Psychiatry. – 2011. – Vol. 72 (1). – P. 75–80.

46. Kim S.W., Shin I.S., Kim J.M. et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial // Prog Neuropsychopharmacol Biol Psychiatry. − 2007. − Vol. 31 (7). − P. 1504–1509.

47. Schreiner A., Bergmans P., Cherubin P., Hargarter L. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole // Ther Adv Psychopharmacol. − 2017, Feb. − Vol. 7 (2). − P. 59−65.

48. Cruz N., Sanchez-Moreno J., Torres F. et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis // Int J Neuropsychopharmacol. − 2010. − Vol. 13 (1). − P. 5–14.

49. Lehman A.F., Lieberman J.A., Dixon L.B. et al. Practice guideline for the treatment of patients with schizophrenia, second edition // Am J Psychiatry. − 2004. − Vol. 161, Suppl. 2. − P. 1–56.

50. Falkai P., Wobrock T., Lieberman J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 2: long-term treatment of schizophrenia // World J Biol Psychiatry. − 2006. − Vol. 7 (1). − P. 5–40.

51. Buchanan R.W., Kreyenbuhl J., Kelly DL. et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements // Schizophr Bull. − 2010. − Vol. 36 (1). − P. 71–93.

52. Mulholland C., Lynch G., King D.J., Cooper S.J. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia // J Psychopharmacol. − 2003. − Vol. 17 (1). − P. 107–112.

53. Addington D., Addington J., Patten S. et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia // J Clin Psychopharmacol. − 2002. − Vol. 22 (1). − P. 20–25.

54. Kirli S., Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia // Schizophr Res. − 1998. − Vol. 33 (1–2). − P. 103–111.

55. Zisook S., Kasckow J.W., Lanouette N.M. et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial // J Clin Psychiatry. − 2010. − Vol. 71 (7). − P. 915–922.

56. Siris S.G. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents // Am J Psychiatry. − 2000. − Vol. 157 (9). − P. 1379–1389.

57. Siris S.G. Suicide and schizophrenia // J Psychopharmacol. – 2001. – Vol. 15 (2). – P. 127–135.

58. Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation // World J Biol Psychiatry. − 2015, Apr. − Vol. 16 (3). − P. 142−170.

59. Luan S., Wan H., Wang S., Li H., Zhang B. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials // Neuropsychiatr Dis Treat. − 2017, Feb 27. − Vol. 13. − P. 609−620.

60. Figueiredo T., Segenreich D., Mattos P. Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients // Journal of Clinical Psychopharmacology. − 2016. − Vol. 36 (4). − P. 389–391.

61. Mazeh D., Shahal B., Saraf R., Melamed Y. Venlafaxine for the treatment of depressive episode during the course of schizophrenia // J Clin Psychopharmacol. − 2004. − Vol. 24 (6). − P. 653–655.

62. Terevnikov V., Stenberg J.H., Tiihonen J. et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase // Hum Psychopharmacol. − 2011. − Vol. 26 (3). − P. 188–193.

63. Englisch S., Inta D., Eer A., Zink M. Bupropion for depression in schizophrenia // Clin Neuropharmacol. − 2010. − Vol. 33 (5). − P. 257–259.

64. Englisch S., Morgen K., Meyer-Lindenberg A., Zink M. Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature // Clin Neuropharmacol. − 2013. − Vol. 36 (6). − P. 203–215.

65. Plasky P. Antidepressant usage in schizophrenia // Schizophr Bull. − 1991. − Vol. 17 (4). − P. 649–657.

66. Siris S.G., Bermanzohn P.C., Mason S.E., Shuwall M.A. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial // Arch Gen Psychiatry. − 1994. − Vol. 51 (2). − P. 109–115.

67. Nelson J.C., Bowers M.B. Jr., Sweeney D.R. Exacerbation of psychosis by tricyclic antidepressants in delusional depression // Am J Psychiatry. − 1979. − Vol. 136 (4B). − P. 574–576.

68. Prusoff B.A., Williams D.H., Weissman M.M., Astrachan B.M. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine // Arch Gen Psychiatry. − 1979. − Vol. 36 (5). − P. 569–575.

69. Helfer B., Samara M.T., Huhn M. et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. // Am J Psychiatry. – 2016. – Vol. 173 (9). – P. 876–886.

70. Xasan A., Falkai P., Vobrok T. i dr. Rukovodstvo po biologicheskoj terapii shizofrenii vsemirnoj federacii obshhestv biologicheskoj psixiatrii (WFSBP). Ch. 1. obnovlennaya redakciya 2012 g. po terapii ostrogo pristupa shizofrenii i terapevticheski rezistentny`x sluchaev // Sovremennaya terapiya psixicheskix rasstrojstv. − 2013. − № TV1. − S. 3−40.

71. Leucht S., Kissling W., McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials // J Clin Psychiatry. − 2004. − Vol. 65 (2). − P. 177–186.

72. Glick I.D., Bosch J., Casey D.E. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive // J Clin Psychopharmacol. − 2009. − Vol. 29 (3). − P. 267–271.

73. Vayisoglu S., Anil Yagcioglu A.E., Yagcioglu S. et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment // Schizophr Res. − 2013. − Vol. 143 (1). − P. 207–214.

74. Leucht S., Helfer B., Dold M., Kissling W., McGrath J.J. Lithium for schizophrenia (Review) // Cochrane Database Syst Rev. – 2015. Vol. 10. – CD003834. – DOI: 10.1002/14651858.CD003834.pub3

75. Wang Y., Xia J., Helfer B., Li C., Leucht S. Valproate for schizophrenia // Cochrane Database Syst Rev. – 2016. – Vol. 11. – CD004028. – DOI: 10.1002/14651858.CD004028.pub4.d

76. Pompili M., Lester D., Dominici G. et al. Indications for electroconvulsive treatment in schizophrenia: a systematic review // Schizophr Res. − 2013. − Vol. 146 (1–3). − P. 1–9.

77. Tharyan P., Adams C. Electroconvulsive therapy for schizophrenia. // Cochrane Database Syst Rev. – 2005. – Vol. 2. – CD000076. – DOI: 10.1002/14651858.CD000076.pub2

78. Munk-Olsen T., Laursen T.M., Videbech P. et al. All-cause mortality among recipients of electroconvulsive therapy: register-based cohort study // Br J Psychiatry. − 2007. − Vol. 190. − P. 435–439.

79. Oleneva E.V., Czukarzi E`.E`., Mosolov S.N. Kombinirovannoe primenenie E`ST i atipichny`x antipsixotikov u bol`ny`x shizofreniej, rezistentny`x k terapii // Social`naya i klinicheskaya psixiatriya. − 2007. − T. 17, № 4. − S. 28−32.

80. Oleneva E.V., Tsukarzi E.E., Mosolov S.N. Combined olanzapine – ECT therapy for resistant schizophrenia // International Journal of Neuropsychopharmacology. − 2008. − Vol. 11, No. S1. − P. S151.

81. Oleneva E.V. Kombinirovannoe primenenie E`ST i atipichny`x antipsixotikov dibenzodiazepinovogo ryada pri terapevticheski rezistentnoj shizofrenii: diss. … kand. med. nauk. – M., 2010.

82. Grover S., Hazari N., Kate N. Combined use of clozapine and ECT: a review // Acta Neuropsychiatr. − 2015, Jun. − Vol. 27 (3). − P. 131−142.

83. Lefaucheur J.P., Andre-Obadia N., Antal A. et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) // Clin Neurophysiol. − 2014. − Vol. 125 (11). − P. 2150–2220.

84. Dougall N., Maayan N., Soares-Weiser K., McDermott L., McIntosh A. Transcranial magnetic stimulation for schizophrenia // Cochrane Database Syst Rev. – 2015. –Vol. 8. – CD006081. – DOI: 10.1002/14651858. CD006081.pub2

85. Maslenikov N., Tsukarzi E., Mosolov S. Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression in schizophrenia patients // Ann Gen Psychiatry. − 2008. − Vol. 7, Suppl. 1. − S. 312.

86. Maslenikov N.V., Czukarzi E`.E`., Mosolov S.N. E`ffektivnost` transkranial`noj magnitnoj stimulyacii pri depressiyax u bol`ny`x shizofreniej // Obozrenie psixiatrii i medicinskoj psixologii imeni V.M. Bextereva. − 2010. − № 2. − S. 14–18.

87. Maslenikov N.V., Czukarzi E`.E`., Mosolov S.N. Transkranial`naya magnitnaya stimulyaciya (TMS) v lechenii depressii i negativnoj simptomatiki pri shizofrenii // Psixicheskoe zdorov`e. − 2013. − T. 11, № 1 (80). − S. 39−44.

88. Wobrock T., Guse B., Cordes J. et al. Left prefrontal high-frequency rTMS for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicentre trial // Biol Psychiatry. − 2015, Jun 1. − Vol. 77 (11). − P. 979−988.

89. Dauwan M., Begemann M.J., Heringa S.M., Sommer I.E. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis // Schizophr Bull. – 2016. – Vol. 42 (3). – P. 588–599.

90. Wykes T., Steel C., Everitt B., Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor // Schizophr Bull. – 2008. – Vol. 34 (3). – P. 523–537.

91. Jones C., Hacker D., Cormac I., Meaden A., Irving C.B. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia // Cochrane Database Syst Rev. – 2012. – Vol. 4 (4). – CD008712. – DOI: 10.1002/14651858.CD008712.pub2

92. Caldwell C.B., Gottesman I.I. Schizophrenics kill themselves too: a review of risk factors for suicide // Schizophr Bull. − 1990. − Vol. 16 (4). − P. 571–589.

93. Meltzer H.Y. Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine // J Clin Psychiatry. − 2005. − Vol. 66 (4). − P. 530–533.

94. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination // Arch Gen Psychiatry. – 2005. – Vol. 62 (3). – P. 247–253.

95. Harvey P.D., Espaillat S. Suicide in schizophrenia // Koslow S.H., Ruiz P., Nemeroff C.B., eds. A Concise Guide to Understanding Suicide Epidemiology: Pathophysiology and Prevention, 1st ed. – Cambridge: Cambridge University Press, 2014. – 406 p.

96. Birchwood M., Iqbal Z., Chadwick P., Trower P. Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression // Br J Psychiatry. − 2000. − Vol. 177. − P. 516–521.

97. Meltzer H.Y., Alphs L., Green A.I. et al. Clozapine treatment for suicidality in schizophrenia // Arch Gen Psychiatry. – 2003. – Vol. 60 (1). – P. 82–91.

98. Hennen J., Baldessarini R.J. Suicidal risk during treatment with clozapine: a meta-analysis // Schizophr Res. – 2005. –Vol. 73 (2–3). – P. 139–145.

99. Xasan A., Falkai P., Vobrok T. i dr. Obnovlennaya redakciya 2012 g. po dlitel`noj terapii shizofrenii i taktike vedeniya pacientov s inducirovanny`mi antipsixoticheskimi preparatami pobochny`mi e`ffektami. Ch. 2 // Sovremennaya terapiya psixicheskix rasstrojstv. − 2014. − № TV2. − S. 3−36.

100. Bandelow B., Zohar J., Kasper S., Möller H.J. How to grade categories of evidence // World J Biol Psychiatry. − 2008. − Vol. 9 (4). − P. 242–247.